東京医科歯科大学臨床試験管理センター 生物統計学・データサイエンス部大学院医歯学総合研究科 臨床統計学分野

主な研究実績

2020

  1. Kaneko S, Hirakawa A, Kakurai Y, Hamada C. A dose-finding approach for genomic patterns in phase I trials. Journal of Biopharmaceutical Statistics, 2020; doi: 10.1080/10543406.2020.1744619.
  2. Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, Kojima Y, Yonemori K, Fujiwara Y, Kinoshita T, Ushijima T, Tamura K. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. Breast Cancer Research and Treatment, 2020; 181: 323-329.
  3. Kato T, Motoji Y, Tamaki M, Inagaki M, Tsunekawa T, Hirakawa A, Okawa Y, Tomita S. Clinical benefits of fast‑track rehabilitation program for patients with uncomplicated type B acute aortic dissection. General Thoracic and Cardiovascular Surgery, 2020; doi:10.1007/s11748-020-01347-w.
  4. Suzuki K, Hirakawa A, Ihara R, Iwata A, Ishii K, Ikeuchi T, Chung-KaiSun, Donohue M, Iwatsubo T. Effect of apolipoprotein E 4 allele on the progression of cognitive decline in the early stage of Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2020; doi: 10.1002/trc2.12007.
  5. Matsumoto T, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Nakano T, Ito M, Tomomitsu T, Hirakawa A, Soen S. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA) Journal of Bone and Mineral Metabolism, 2020; doi: 10.1007/s00774-020-01091-4.
  6. Kawase Y, Omori H, Tanigaki T, Hirakawa A, Hirata T, Ota H, Kikuchi J, Sobue Y, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Matsuo H. In vivo validation of resting full-cycle ratio and diastolic pressure ratio – simultaneous measurement with instantaneous wave-free ratio. Cardiovascular Intervention and Therapeutics, 2020; doi: 10.1007/s12928-020-00648-4.
  7. Hattori M, Tsuboi T, Yokoi K, Tanaka Y, Sato M, Suzuki K, Arahata Y, Hori A, Kawashima M, Hirakawa A, Washimi Y, Watanabe H, Katsuno M. Subjects at risk of Parkinson’s disease in health checkup examinees: cross-sectional analysis of baseline data of the NaT-PROBE study. Journal of Neurology, 2020; doi: 10.1007/s00415-020-09714-6.
  8. Okuma HS, Yonemori K, Narita SN, Sukigara T, Hirakawa A, Shimizu T, Shibata T, Kawai A, Yamamoto N, Nakamura K, Nishida T, Fujiwara Y. MASTER KEY Project: Powering Clinical Development for Rare Cancers through a Platform Trial. Clinical Pharmacology & Therapeutics, 2020; doi: 10.1002/cpt.1817.
  9. Nishizawa M, Onodera O, Hirakawa A, Shimizu Y, Yamada M; Rovatirelin Study Group. Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials. Journal of Neurology, Neurosurgery & Psychiatry, 2020; 91: 254-262.
  10. Soen S, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Ito M, Nakano T, Hagino H, Hirakawa A, Matsumoto T. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study. Journal of Bone and Mineral Metabolism, 2020; doi: 10.1007/s00774-019-01077-x.
  11. Kato M, Hirakawa A, Kobayashi Y, Yamamoto A, Ishida R, Kamihira O, Sano T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Hattori R, Gotoh M, Tsuzuki T. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients. The Prostate, 2020; 80: 284-290.
  12. Sakakibara S, Hashimoto R, Katayama T, Kenjyo M, Yokokawa Y, Saito Y, Hirakawa A, Ito M, Nakamura T, Hara K, Hashizume A, Aiba I, Inukai A, Katsuno M. Longitudinal change of DAT SPECT in Parkinson’s disease and multiple system atrophy. Journal of Parkinson’s Disease, 2020; doi: 10.3233/JPD-191710.
  13. Asano J and Hirakawa A. A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations. Pharmaceutical Statistics, 2020; https://doi.org/10.1002/pst.2049.
  14. Kaneko S and Hirakawa A. Assessment of overall treatment effect in the presence of inconsistent regional effects in multi-regional clinical trials. Statistics in Biopharmaceutical Research, 2020; https://doi.org/10.1080/19466315.2020.1845233.

2019

  1. Hirakawa A, Sudo K, Yonemori K, Sadachi R, Kinoshita F, Kobayashi Y, Okuma HS, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Takebe N. A comparative study of longitudinal toxicities of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, and cancer vaccines. Clinical Pharmacology & Therapeutics, 2019; 106: 803-809.
  2. Kakurai Y, Kaneko S, Hamada C, Hirakawa A (corresponding author). Dose individualization and variable selection using Bayesian Lasso in early phase dose-finding trials. Applied Statistics, 2019; 68: 445-460.
  3. Kada A, Hirakawa A (co-first author), Kinoshita F, Kobayashi Y, Hatakeyama T, Kobayashi D, Nishiyama C, Iwami T. Sample size estimation and re-estimation of cluster randomized controlled trials for real-time feedback, debriefing, and retraining system of cardiopulmonary resuscitation for out-of-hospital cardiac arrests. Contemporary Clinical Trials Communications, 2019; 14: 100316.
  4. Hirakawa A, Tanaka Y, Kaneko S. Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials. Contemporary Clinical Trial Communications, 2019; doi: 10.1016/j.conctc.2019.100489.
  5. Ito D, Hashizume A, Hijikata Y, Yamada S, Iguchi Y, Iida M, Kishimoto Y, Moriyoshi H, Hirakawa A, Katsuno M. Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. Journal of Neurology, 2019; doi: 10.1007/s00415-019-09507-6.
  6. Hirata T, Tanigaki T, Kawase Y, Hirakawa A, Omori H, Okamoto S, Ota H, Sobue Y, Kikuchi J, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Pijls NHJ, Matsuo H. Post-occlusional hyperemia for fractional flow reserve assessment and pull-back curve analysis. Cardiovascular Intervention and Therapeutics, 2019; doi: 10.1007/s12928-019-00579-9.
  7. Hashizume A, Katsuno M, Suzuki K, Banno H, Takeuchi Y, Kawashima M, Suga N, Mano T, Araki A, Hijikata Y, Hirakawa A, Sobue G; JASMITT study group. Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials. Journal of Neurology, 2019; 266: 1211-1221.
  8. Yoshimi A, Yamada S, Kunimoto S, Aleksic B, Hirakawa A, Ohashi M, Matsumoto Y, Hada K, Itoh N, Arioka Y, Kimura H, Kushima I, Nakamura Y, Shiino T, Mori D, Tanaka S, Hamada S, Noda Y, Nagai T, Yamada K, Ozaki N. Proteomic analysis of lymphoblastoid cell lines from schizophrenic patients. Translational Psychiatry, 2019; 9: 126.
  9. Shimizu S, Tsuchiya S, Hirakawa A, Kato K, Ando M, Mizuno M, Osugi M, Okabe K, Katagiri W, Hibi H. Design of a Randomized Controlled Clinical Study of tissue-engineered osteogenic materials using bone marrow-derived mesenchymal cells for Maxillomandibular bone defects in Japan: the TEOM study protocol. BMC Oral Health, 2019; 19: 69.
  10. Kato M, Hirakawa A, Kobayashi Y, Yamamoto A, Ishida R, Sano T, Kimura T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Yamamoto T, Hattori R, Gotoh M, Tsuzuki T. The influence of the presence of intraductal carcinoma of the prostate on the grade group system’s prognostic performance. The Prostate, 2019; doi: 10.1002/pros.23818.
  11. Takano N, Yamada S, Hirakawa A, Yokoyama Y, Kawashima H, Maeda O, Okada T, Ohno E, Yamaguchi J, Ishikawa T, Sonohara F, Suenaga M, Takami H, Hayashi M, Niwa Y, Hirooka Y, Ito Y, Naganawa S, Ando Y, Nagino M, Goto H, Fujii T, Kodera Y. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study. Nagoya Journal of Medical Science, 2019; 81: 233-239.
  12. Yokoyama T, Miyahara R, Funasaka K, Furukawa K, Yamamura T, Ohno E, Nakamura M, Kawashima H, Watanabe O, Hirooka Y, Hirakawa A, Goto H. The utility of ultrathin endoscopy with flexible spectral imaging color enhancement for early gastric cancer. Nagoya Journal of Medical Science, 2019; 81: 241-248.
  13. Taniguchi A, Kawada JI, Go K, Fujishiro N, Hosokawa Y, Maki Y, Sugiyama Y, Suzuki M, Tsuji T, Hoshino S, Muramatsu H, Kidokoro H, Kinoshita F, Hirakawa A, Takahashi Y, Sato Y, Natsume J. Comparison of clinical characteristics of human metapneumovirus and respiratory syncytial virus infection in hospitalized young children. Japanese Journal of Infectious Diseases, 2019; 72: 237-242.
  14. Ikenaka K, Atsuta N, Maeda Y, Hotta Y, Nakamura R, Kawai K, Yokoi D, Hirakawa A, Taniguchi A, Morita M, Mizoguchi K, Mochizuki H, Kimura K, Katsuno M, Sobue G. Increase of arginine dimethylation correlates with the progression and prognosis of ALS. Neurology, 2019; 92: e1868-e1877.
  15. Maeda T, Sato Y, Hirakawa A, Nakatochi M, Kinoshita F, Suzuki T, Ichimura S, Ito R, Kudo R, Suzuki M, Hoshino S, Sugiyama Y, Muramatsu H, Kidokoro H, Kawada JI, Takahashi Y. Design of a prospective multicenter randomized controlled trial evaluating the effects of gastric lavage on coffee-ground emesis in neonates: study protocol. Nagoya Journal of Medical Science, 2019; 81: 227-232.
  16. Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. European Journal of Cancer, 2019; 109: 84-91.
  17. Kato M, Hirakawa A, Kobayashi Y, Yamamoto A, Ishida R, Kamihira O, Kimura T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Yamamoto T, Hattori R, Gotoh M, Tsuzuki T. Integrating Tertiary Gleason Pattern 5 into the ISUP Grading System Improves Prediction of Biochemical Recurrence in Radical Prostatectomy Patients. Modern Pathology, 2019; 32: 122-127.
  18. Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Yamazaki N, Fujimoto M, Tamura K, Fujiwara Y. Anti-cancer agent-induced life-threatening skin toxicities: A database study of spontaneous reporting data. The Oncologist, 2019; 24: 266-272.
  19. Imai K, Kotani T, Nakano T, Ushida T, Hirakawa A, Kikkawa F. Maternal protein S activity is associated with massive hemorrhage during Caesarean section: Retrospective case-control study. The Journal of Maternal-Fetal & Neonatal Medicine, 2019; 28: 2633-2637.
  20. 平川晃弘,浅野淳一,佐藤宏征,橋本大哉,手良向聡. がん臨床試験におけるベイズ流バスケットデザインの理論と実装. 計量生物学,2019; 39: 103-122.
  21. 平川晃弘,浅野淳一,佐藤宏征,手良向聡. マスタープロトコルに基づくがん臨床試験. 計量生物学,2019; 39: 85-101.
  22. 大熊ひとみ,平川晃弘,米盛勧. MASTER KEYプロジェクト-希少がんに対するレジストリ・バスケット臨床研究. 腫瘍内科, 2019; 22: 435-442.

2018

  1. Hirakawa A, Asano J, Sato H, Teramukai S. Master protocol trials in oncology: Review and new trial designs. Contemporary Clinical Trial Communications, 2018; 12: 1-8.
  2. Hirakawa A, Hatakeyama T, Kobayashi D, Nishiyama C, Kada A, Kiguchi T, Kawamura T, Iwami T. Real-time feedback, debriefing, and retraining system of cardiopulmonary resuscitation for out-of-hospital cardiac arrests: study protocol for a randomized controlled trial. Trials, 2018; 19: 510.
  3. Shimamura F, Hamada C, Matsui S, Hirakawa A (corresponding author). Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials. Journal of Biopharmaceutical Statistics, 2018; 28: 1025-1037.
  4. Hirakawa A, Yonemori K, Kinoshita F, Kobayashi Y, Okuma H. Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Harris PJ, Takebe N. Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trial. Cancer Science, 2018; 109: 207-214.
  5. Hirakawa A, Nishikawa T, Yonemori K, Shibata T, Nakamura K, Ando M, Ueda T, Ozaki T, Tamura K, Kawai A, Fujiwara Y. Utility of Bayesian single-arm design in new drug application for rare cancers in Japan: a case study of phase 2 trial for sarcoma. Therapeutic Innovation & Regulatory Science, 2018; 52: 334-338.
  6. Nomura S, Hirakawa A, Hamada C. Sample size determination for the current strategy in oncology phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework. Journal of Biopharmaceutical Statistics, 2018; 8: 589-611.
  7. Sato Y, Ueda K, Kondo T, Hattori T, Mikrogeorgiou A, Sugiyama Y, Suzuki T, Yamamoto M, Hirata H, Hirakawa A, Nakanishi K, Tsuji M, Hayakawa M. Administration of Bone Marrow-Derived Mononuclear Cells Contributed to the Reduction of Hypoxic-Ischemic Brain Injury in Neonatal Rats. Frontiers in Neurology, 2018; 9: 987.
  8. Saji N, Sakurai T, Ito K, Tomimoto H, Kitagawa K, Miwa K, Tanaka Y, Kozaki K, Kario K, Eto M, Suzuki K, Shimizu A, Niida S, Hirakawa A, Toba K; Strawberry study investigators. Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study). BMJ Open, 2018; 8: e021759.
  9. Yamada S, Hashizume A, Hijikata Y, Inagaki T, Ito D, Kinoshita F, Nakatochi M, Kobayashi Y, Hirakawa A, Nakamura T, Katsuno M. Study protocol for the MEXiletine hydrochloride administration trial: A placebo-controlled, randomised, double-blind, multicentre, crossover study of its efficacy and safety in spinal and bulbar muscular atrophy (MEXPRESS). BMJ Open, 2018; 8: e023041.
  10. Kawamura I, Kajiura R, Motoji Y, Okamoto S, Tanigaki T, Omori H, Hirata T, Kikuchi J, Ota H, Sobue Y, Miyake T, Tsunekawa T, Kato T, Kawase Y, Okubo M, Kamiya H, Tsuchiya K, Tomita S, Hirakawa A, Kondo T, Suzuki T, Matsuo H. Diagnostic Performance of the Simultaneous Acquisition Rest 99mTc-Tetrofosmin/Stress 201Tl Dual Isotope Protocol with a Semiconductor Camera: Comparison with the Rest-Stress 99mTc-Tetrofosmin Protocol. Circulation Journal, 2018; 82: 2837-2844.
  11. Sakamoto Y, Okamoto S, Shimizu K, Araki Y, Hirakawa A, Wakabayashi T. Comparative Prospective Study of Microvascular Anastomosis Training by Self-Learning or with Expert Instruction. World Neurosurgery, 2018; 118: e818-e824.
  12. Tsuda H, Kotani T, Nakano T, Imai K, Ushida T, Hirakawa A, Kinoshita F, Takahashi Y, Iwagaki S, Kikkawa F. The impact of fertility treatment on the neonatal respiratory outcomes and amniotic lamellar body counts in twin pregnancies. Clinica Chimica Acta, 2018; 484: 192-196.
  13. Tsuda H, Kotani T, Nakano T, Imai K, Ushida T, Hirakawa A, Kinoshita F, Takahashi Y, Iwagaki S, Kikkawa F. The rate of neonatal respiratory distress syndrome/transient tachypnea in the newborn and the amniotic lamellar body count in twin pregnancies compared with singleton pregnancies. Clinica Chimica Acta, 2018; 484: 293-297.
  14. Goto T, Murata M, Terakura S, Nishida T, Adachi Y, Ushijima Y, Shimada K, Ishikawa Y, Hayakawa F, Nishio N, Nishiwaki S, Hirakawa A, Kato K, Takahashi Y, Kiyoi H. Phase I study of cord blood transplantation with intra-bone marrow injection of mesenchymal stem cells: A clinical study protocol. Medicine, 2018; 97: e0449.
  15. Ohsawa Y, Hagiwara H, Nishimatsu SI, Hirakawa A, Kamimura N, Ohtsubo H, Fukai Y, Murakami T, Koga Y, Goto YI, Ohta S, Sunada Y; KN01 Study Group. Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. Journal of Neurology, Neurosurgery, and Psychiatry, 2018; doi: 10.1136/jnnp-2018-317964.
  16. Ogawa C, Sato Y, Suzuki C, Mano A, Tashiro A, Niwa T, Hamazaki S, Tanahashi Y, Suzumura M, Hayano S, Hayakawa M, Tsuji T, Hoshino S, Sugiyama Y, Kidokoro H, Kawada JI, Muramatsu H, Hirakawa A, Ando M, Natsume J, Kojima S. Treatment with silver nitrate versus topical steroid treatment for umbilical granuloma: a non-inferiority randomized control trial. PLOS ONE, 2018; 13: e0192688.
  17. Kawase Y, Kawasaki M, Kikuchi J, Hirata T, Okamoto S, Tanigaki T, Omori H, Ota H, Okubo M, Kamiya H, Hirakawa A, Matsuo H. Residual pressure gradient across the implanted stent: An important factor of post-PCI physiological results. Journal of Cardiology, 2018; 71: 458-463.
  18. Hijikata Y, Hashizume A, Yamada S, Inagaki T, Ito D, Hirakawa A, Suzuki K, Atsuta N, Tsuboi T, Hattori M, Hori A, Banno H, Sobue G, Katsuno M. Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy. Neurology, 2018; 90: e1501-e1509.
  19. Hijikata Y, Katsuno M, Suzuki K, Hashizume A, Araki A, Yamada S, Inagaki T, Ito D, Hirakawa A, Kinoshita F, Gosho M, Sobue G. Treatment with creatine monohydrate in spinal and bulbar muscular atrophy: study protocol for a randomized, double-blind, placebo-controlled trial. JMIR Research Protocol, 2018; 7: e69.
  20. Ogawa C, Kidokoro H, Fukasawa T, Yamamoto H, Ishihara N, Ito Y, Sakaguchi Y, Okai Y, Ohno A, Nakata T, Azuma Y, Hattori A, Kubota T, Tsuji T, Hirakawa A, Kawai H, Natsume J. Cytotoxic edema at onset in West syndrome of unknown etiology: a longitudinal DTI study. Epilepsia, 2018; doi: 10.1111/epi.13988.
  21. 大熊ひとみ,平川晃弘,米盛勧.希少がんに対する新薬開発の取り組みと課題~MASTER KEYプロジェクト~.血液内科, 2018; 76: 806-812.
  22. 大熊ひとみ,平川晃弘,米盛勧,川井章.MSTER KEYプロジェクト.がん分子標的治療, 2018; 16: 16-20.

2017

  1. Hirakawa A, Kinoshita F. An analysis of Japanese patients enrolled into multiregional clinical trials in oncology. Therapeutic Innovation & Regulatory Science, 2017; 51: 207–211.
  2. Gosho M, Maruo K, Tada K, Hirakawa A. Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems. European Journal of Clinical Pharmacology, 2017; 73: 779-786.
  3. Shimura M, Gosho M, Hirakawa A. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data. Statistics in Medicine, 2017; 36: 2067-2080.
  4. Asano J, Hirakawa A (co-first author). Assessing the prediction accuracy of a cure model for censored survival data with long-term survivors: application to breast cancer data. Journal of Biopharmaceutical Statistics, 2017; doi: 10.1080/10543406.2017.1293082.
  5. Miyauchi R, Itoh Y, Kawamura M, Hirakawa A, Shibata K, Kajiyama H, Nakahara R, Kubota S, Ito J, Okada T, Kikkawa F, Naganawa S. Postoperative chemoradiation therapy using high dose cisplatin and fluorouracil for high- and intermediate-risk uterine cervical cancer. Nagoya Journal of Medical Science, 2017; 79: 211-220.
  6. Miyamoto K, Ohkawara B, Ito M, Masuda A, Hirakawa A, Sakai T, Hiraiwa H, Hamada T, Ishiguro N, Ohno K. Fluoxetine ameliorates cartilage degradation in osteoarthritis by inhibiting Wnt/β-catenin signaling. PLoS One, 2017; 12: e0184388.
  7. Sawamura A, Okumura T, Hirakawa A, Ito M, Ozaki Y, Ohte N, Amano T, Murohara T; CHANGE PUMP Investigators. Early Prediction Model for Successful Bridge to Recovery in Patients With Fulminant Myocarditis Supported With Percutaneous Venoarterial Extracorporeal Membrane Oxygenation – Insights From the CHANGE PUMP Study. Circulation Journal, 2017; doi: 10.1253/circj.CJ-17-0549.
  8. Ozeki N, Fukui T, Kawaguchi K, Nakamura S, Hakiri S, Kato T, Hirakawa A, Yokoi K. A survival analysis using physique-adjusted tumor size of non-small cell lung cancer. International Journal of Clinical Oncology, 2017; doi: 10.1007/s10147-017-1219-6.
  9. Kawase Y, Kawasaki M, Tanigaki T, Omori H, Hirata T, Okamoto S, Ota H, Kikuchi J, Okubo M, Kamiya H, Hirakawa A, Suzuki T, Matsuo H. Postocclusional hyperemia for fractional flow reserve after percutaneous coronary intervention. JACC-Cardiovascular Interventions, 2017; doi: 10.1161/CIRCINTERVENTIONS.117.005674.
  10. Kato M, Kimura K, Hirakawa A, Kobayashi Y, Ishida R, Kamihira O, Majima T, Funahashi Y1, Sassa N, Matsukawa Y, Hattori R, Gotoh M, Tsuzuki T. Prognostic parameter for high risk prostate cancer patients at initial presentation. Prostate, 2018; 78: 11-16.
  11. Shimizu S, Yamamoto T, Nakayama S, Hirakawa A, Kuwatsuka Y, Funahashi Y, Matsukawa Y, Takanari K, Toriyama K, Kamei Y, Narimoto K, Yamanishi T, Ishizuka O, Mizuno M, Gotoh M. Design of a single-arm clinical trial of regenerative therapy by periurethral injection of adipose-derived regenerative cells for male stress urinary incontinence in Japan: the ADRESU study protocol. BMC Urology, 2017; 17: 89.
  12. Yokoi A, Yoshioka Y, Hirakawa A, Yamamoto Y, Ishikawa M, Ikeda S, Kato T, Niimi K, Kajiyama H, Kikkawa F, Ochiya T. A combination of circulating miRNAs for the early detection of ovarian cancer. Oncotarget, 2017; 8: 89811-89823.
  13. Chantarojanasiri T, Hirooka Y, Kawashima H, Ohno E, Kuwahara T, Yamamura T, Funasaka K, Nakamura M, Miyahara R, Ishigami M, Watanabe O, Hashimoto S, Hirakawa A, Ratanachu-ek T, Goto H. Endoscopic ultrasound in diagnosis of solid pancreatic lesions: Elastography or contrast-enhanced harmonic alone versus the combination. Endoscopy International Open, 2017; 5: E1136-E1143.
  14. Kawase Y, Tanigaki T, Hirakawa A, Omori H, Hirata T, Okamoto S, Ota H, Kikuchi J, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Matsuo H. Frequency of a large drift caused by pressure wire using optical fibers. Cardiovascular Intervention and Therapeutics, 2017; doi: 10.1007/s12928-017-0481-x.
  15. Hyodo R, Sato Y, Ito M, Sugiyama Y, Ogawa C, Kawai H, Nakane T, Saito A, Hirakawa A, Kidokoro H, Natsume J, Hayakawa M. Magnetic resonance spectroscopy in preterm infants: association with neurodevelopmental outcomes. Archives of Disease in Childhood, 2017; doi: 10.1136/archdischild-2016-311403.
  16. Hashizume A, Katsuno M, Suzuki K, Hirakawa A, Hijikata Y, Yamada S, Inagataki T, Banno M, Sobue G. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy -Natural history-controlled study- Journal of Neurology, Neurosurgery, and Psychiatry, 2017; 88: 1026-1032.
  17. Ozeki N, Kawaguchi K, Fukui T, Fukumoto K, Nakamura S, Hakiri S, Kato T, Hirakawa A, Okasaka T, Yokoi K. The diffusing capacity of the lung for carbon monoxide is associated with the histopathological aggressiveness of lung adenocarcinoma, European Journal of Cardio-Thoracic Surgery, 2017; 52: 969-974.
  18. Sakamoto Y, Okamoto S, Shimizu K, Araki Y, Hirakawa A, Wakabayashi T. Hands-on simulation versus traditional video-learning in teaching microsurgery technique. Neurologia Medico-Chirurgica, 2017; 57: 238-245.
  19. Nakanishi K, Sato Y, Mizutani Y, Ito M, Hirakawa A, Higashi Y. Rat umbilical cord blood cells attenuate hypoxic-ischemic brain injury in neonatal rats. Scientific Reports, 2017; 7: 44111.
  20. Kato T, Tamaki M, Tsunekawa T, Motoji Y, Hirakawa A, Okawa Y, Tomita S. Health-Related Quality of Life Prospectively Evaluated by the 8-item Short Form After Endovascular Repair Versus Open Surgery for Abdominal Aortic Aneurysms. Heart Vessel, 2017; doi: 10.1007/s00380-017-0956-9.
  21. Imai K, Kotani T, Tsuda H, Nakano T, Hirakawa A, Kikkawa F. A Novel Approach to Detecting Postpartum Hemorrhage Using Contrast-Enhanced Ultrasound. Ultrasound in medicine and biology, 2017; 43: 615-620.
  22. Kato T, Tsunekawa T, Motoji Y, Hirakawa A, Okawa Y, Tomita S. The side-to-side fashion for individual distal coronary anastomosis using venous conduit. Heart and Vessels, 2017; 32: 385-389.
  23. Suzuki N, Hirakawa A, Kishimoto M, Kanematsu T, Ogawa M, Kiyoi H, Matsushita T. Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study. Haemophilia, 2017; 23: 215-221.
  24. Yamasaki S, Hirakawa A, Aoki J, Uchida N, Fukuda T, Ogawa H, Ohashi K, Kondo T, Eto T, Kanamori H, Okumura H, Iwato K, Ichinohe T, Kanda J, Onizuka M, Kuwatsuka Y, Yanada M, Atsuta Y, Takami A, Yano S. Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia. Annals of Hematology, 2017; 96: 289-297.
  25. 小川 千香子, 三浦 清邦, 伊藤 祐史, 城所 博之, 平川 晃弘, 根来 民子, 夏目 淳. 重症心身障害児を持つ親の離婚. 日本小児科学会雑誌, 2017; 121: 563.